Key Points
- Director George Jenkins sold 7,174 Palvella shares for approximately $935,203 at an average price of $130.36, reducing his stake by 4.88%. The transaction was made under a pre-arranged Rule 10b5-1 trading plan.
- Palvella reported a quarterly loss of $1.52 per share, missing the consensus estimate of a $1.17 loss. Analysts project a full-year loss of $6.40 per share.
- Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $207.43, despite some lowered forecasts and the stock trading well below several analyst targets.
Palvella Therapeutics, Inc. (NASDAQ:PVLA - Get Free Report) Director George Jenkins sold 7,174 shares of the company's stock in a transaction dated Tuesday, October 13th. The stock was sold at an average price of $130.36, for a total transaction of $935,202.64. Following the completion of the transaction, the director owned 139,790 shares in the company, valued at approximately $18,223,024.40. The trade was a 4.88% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Palvella Therapeutics Price Performance
Shares of PVLA stock opened at $122.58 on Thursday. Palvella Therapeutics, Inc. has a one year low of $68.96 and a one year high of $161.38. The company's 50-day moving average is $146.74 and its 200 day moving average is $134.32.
Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.35). Analysts predict that Palvella Therapeutics, Inc. will post -6.40 earnings per share for the current year.
Wall Street Analyst Weigh In
Several research analysts have recently weighed in on the company. Canaccord Genuity Group set a $232.00 price target on Palvella Therapeutics in a research note on Wednesday, August 5th. HC Wainwright dropped their price objective on Palvella Therapeutics from $270.00 to $246.00 and set a "buy" rating on the stock in a research report on Monday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Palvella Therapeutics in a research report on Friday, September 25th. Truist Financial set a $207.00 price objective on Palvella Therapeutics in a report on Wednesday, August 5th. Finally, Chardan Capital started coverage on Palvella Therapeutics in a report on Monday, September 21st. They issued a "buy" rating and a $240.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $207.43.
Get Our Latest Stock Analysis on PVLA
Key Stories Impacting Palvella Therapeutics
Here are the key news stories impacting Palvella Therapeutics this week:
- Positive Sentiment: HC Wainwright maintained a Buy rating and $246 price target. Despite lowering its earnings forecasts, the analyst’s target remains well above recent trading levels, indicating continued confidence in Palvella’s longer-term opportunity. HC Wainwright analyst coverage
- Neutral Sentiment: Management will participate in the Chardan 10th Annual Healthcare Conference on October 20. The fireside chat could provide updates on Palvella’s development programs for rare skin diseases and vascular anomalies, although no new clinical or regulatory information was announced. Palvella Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference
- Negative Sentiment: HC Wainwright significantly reduced its projected earnings for 2027 through 2030. Estimates were cut to losses of $13.52 per share in 2027, $10.40 in 2028 and $4.84 in 2029, while the 2030 forecast was reduced to $5.82 from $19.10. The revisions suggest a slower path to profitability and likely contributed to the stock’s decline.
- Negative Sentiment: Director George Jenkins sold 20,326 shares worth approximately $2.69 million across October 12 and 13. The transactions reduced his direct ownership by roughly 13% overall. Both sales were conducted under a pre-arranged Rule 10b5-1 trading plan, which may lessen their significance, but the sizable insider selling can still weigh on investor sentiment. Palvella Therapeutics SEC insider transaction filing
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new stake in Palvella Therapeutics in the second quarter worth approximately $140,343,000. First Light Asset Management LLC grew its position in Palvella Therapeutics by 38.3% in the 1st quarter. First Light Asset Management LLC now owns 980,758 shares of the company's stock worth $122,251,000 after purchasing an additional 271,617 shares during the period. Jennison Associates LLC grew its position in Palvella Therapeutics by 65.3% in the 1st quarter. Jennison Associates LLC now owns 640,611 shares of the company's stock worth $79,852,000 after purchasing an additional 253,128 shares during the period. Summit Partners Public Asset Management LLC grew its position in Palvella Therapeutics by 1,016.0% in the 4th quarter. Summit Partners Public Asset Management LLC now owns 389,420 shares of the company's stock worth $40,761,000 after purchasing an additional 354,525 shares during the period. Finally, Primecap Management Co. CA purchased a new stake in Palvella Therapeutics during the 2nd quarter valued at $39,150,000. Institutional investors own 40.11% of the company's stock.
About Palvella Therapeutics
(
Get Free Report)
Palvella Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for patients with rare and serious diseases. The company's work centers on localized treatments intended to address conditions for which existing therapeutic options are limited.
Palvella's lead investigational product is QTORIN 3.9%, a topical formulation of sirolimus designed to deliver the medicine directly to affected areas of the skin. The product is being developed for microcystic lymphatic malformations, rare vascular anomalies that can cause swelling, pain and disfigurement.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
